Ribavirin
- Generic Name
- Ribavirin
- Brand Names
- Ibavyr, Rebetol, Virazole
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 36791-04-5
- Unique Ingredient Identifier
- 49717AWG6K
- Background
Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...
- Indication
Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
- Associated Therapies
- -
Study of Oral Treatments for Hepatitis C
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 1275
- Registration Number
- NCT02786537
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸University of Florida, Jacksonville, Jacksonville, Florida, United States
🇺🇸Internal Medicine Associates of Wellstar Atlanta Medical Center, Atlanta, Georgia, United States
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 204
- Registration Number
- NCT02781558
- Locations
- 🇪🇸
Hospital Universitario Donostia, San Sebastian, Spain
🇪🇸Hospital Universitario Virgen De La Arrixaca, Murcia, Spain
🇪🇸Complexo Hospitalario Universitario de Montecelo, Pontevedra, Spain
Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
- Conditions
- Interventions
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 10
- Registration Number
- NCT02781649
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2016-05-13
- Target Recruit Count
- 150
- Registration Number
- NCT02771405
- Locations
- 🇪🇬
Amr Maged, Cairo, Egypt
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
- Conditions
- Interventions
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 180
- Registration Number
- NCT02761629
Extrahepatic Insulin Resistance in Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 17
- Registration Number
- NCT02760355
- Locations
- 🇨🇭
Division of Gastroenterology and hepatology, University Hospital, Geneva, GE, Switzerland
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 239
- Registration Number
- NCT02738333
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
- Conditions
- Interventions
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02731131
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 216
- Registration Number
- NCT02725866
A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT02726022
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.